Publications

Talk to Our Care Team

Development of equitable access model for nationwide implementation of affordable CAR-T cell therapy in India: a real-world experience.

Article

May 10, 2025
Cytotherapy
View Article

Novel humanized CD19-CAR-T (Now talicabtagene autoleucel, Tali-cel™) cells in relapsed/ refractory pediatric B-acute lymphoblastic leukemia- an open-label single-arm phase-I/Ib study

Article

Apr 24, 2025
Blood Cancer Journal
View Article

Talicabtagene Autoleucel for Relapsed or Refractory B-cell Malignancies: Results from an Open-label, Multicentre, Phase 1/2 Study

Article

Apr 1, 2025
The Lancent Haematology
View Article

Real world data of novel Talicabtagene autoleucel (humanized CD19 CAR-T) from India; ensuring equitable access with excellent safety and efficacy profile

Poster

Dec 7, 2024
American Society of Hematology Meeting
View Poster

Real world data of novel Talicabtagene autoleucel (humanized CD19 CAR-T) from India; ensuring equitable access with excellent safety and efficacy profile

Abstract

Nov 5, 2024
Blood
View Abstract

Development of a Novel Humanized BCMA-Directed CAR for Multiple Myeloma: Robust Activity and Low Toxicity in Preclinical Studies

Poster

Dec 7, 2024
American Society of Hematology Meeting
View Poster

Development of a Novel Humanized BCMA-Directed CAR for Multiple Myeloma: Robust Activity and Low Toxicity in Preclinical Studies

Abstract

Nov 5, 2024
Blood
View Abstract

High Efficacy and Excellent Safety Profile of Actalycabtagene Autoleucel, a Humanized CD19 CAR-T Product in r/r B-Cell Malignancies: A Phase II Pivotal Trial

Poster

Dec 9, 2023
American Society of Hematology Meeting
View Poster

High Efficacy and Excellent Safety Profile of Actalycabtagene Autoleucel, a Humanized CD19 CAR-T Product in r/r B-Cell Malignancies: A Phase II Pivotal Trial

Abstract

Nov 2, 2023
Blood
View Abstract

Excellent Safety Profile of a Low-Cost Novel Humanized CD19 CAR T-Cell Therapy, Actalycabtagene Autoleucel : Potential Impact on Access and Feasibility

Poster

Dec 9, 2023
American Society of Hematology Meeting
View Poster

Excellent Safety Profile of a Low-Cost Novel Humanized CD19 CAR T-Cell Therapy, Actalycabtagene Autoleucel : Potential Impact on Access and Feasibility

Abstract

Nov 2, 2023
Blood
View Abstract

Making Anti-CD19 CAR-T Cell Therapy Accessible and Affordable: First-in-Human Phase I Clinical Trial Experience from India

Poster

Dec 10, 2022
American Society of Hematology Meeting
View Poster

Making Anti-CD19 CAR-T Cell Therapy Accessible and Affordable: First-in-Human Phase I Clinical Trial Experience from India

Abstract

Nov 15, 2022
Blood
View Abstract

Robust Antitumor Activity and Low Cytokine Production by Novel Humanized Anti-CD19 CAR T Cells

Article

May 1, 2021
Moecular Cancer Therapeutics
View Article
Let's Get in Touch with
ImmunoACT Logo